DOW JONES25,409.36-357.28 -1.39%
S&P 5002,954.22-24.54 -0.82%
NASDAQ8,567.37+0.89 0.01%

Wedbush Downgrades Syros Pharmaceuticals to Neutral, Announces $9 Price Target

Wedbush downgrades Syros Pharmaceuticals (NASDAQ:SYRS) from Outperform to Neutral and announces $9 price target.

Benzinga · 01/17/2020 12:18

Wedbush downgrades Syros Pharmaceuticals (NASDAQ:SYRS) from Outperform to Neutral and announces $9 price target.